<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089904</url>
  </required_header>
  <id_info>
    <org_study_id>IRB19-0310</org_study_id>
    <nct_id>NCT04089904</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma</brief_title>
  <official_title>A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA&#xD;
      treated with neoadjuvant pembrolizumab followed by surgical resection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate</measure>
    <time_frame>11 weeks</time_frame>
    <description>Determine the pCR rate in patients with gastroesophageal adenocarcinoma (GEA) treated with neoadjuvant pembrolizumab followed by surgery. Regression of the primary tumor will be documented by the amount of viable tumor verses the amount of fibrosis using Becker Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basic reproduction number (R0) resection rate</measure>
    <time_frame>11 weeks</time_frame>
    <description>GEA patients treated with neoadjuvant pembrolizumab using proximal, distal and circumferential margins to determine the completeness of resection. The absence of tumor cells at the proximal and distal margins will be required to be classified as an R0 resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Response Grades (PRG)</measure>
    <time_frame>11 weeks</time_frame>
    <description>To determine rates of grade 1a (complete), 1b(minimal residual disease), 2 (partial response) and 3 (no response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with GEA taking pembrolizumab with treatment-related adverse events</measure>
    <time_frame>11 weeks</time_frame>
    <description>Evaluate the safety/tolerability patient response of pembrolizumab in patients with GEA. Number of patients with GEA taking pembrolizumab with treatment-related adverse events as assessed by CTCAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival rate (DFS)</measure>
    <time_frame>11 weeks</time_frame>
    <description>to determine the DFS rate measured from the time of the first pembrolizumab dose and compare with patients who have surgery only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival rate (OS)</measure>
    <time_frame>11 weeks</time_frame>
    <description>to determine the overall survival rate of patients measured from the time of first pembrolizumab dose compared to patients who have surgery only</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Male/female participants who are at least 18 years of age on the day of signing&#xD;
             informed consent with histologically confirmed diagnosis of untreated esophageal&#xD;
             adenocarcinoma (AC) (including Siewert type I and II esophagogastric junction AC) or&#xD;
             gastric AC (including Siewert type III esophagogastric junction AC), with clinical&#xD;
             stage T1b-T2, N0, and M0.&#xD;
&#xD;
          2. Patients must undergo endoscopic ultrasound (EUS), CT chest/abdomen/pelvis with IV/PO&#xD;
             contrast (MRI abdomen/pelvis plus noncontrast chest CT is acceptable if patient has a&#xD;
             contraindication to iodinated dye), and PET/CT to complete staging and confirm absence&#xD;
             of metastatic disease.&#xD;
&#xD;
          3. HER2+ and HER2- patients, and all other known molecular subsets are eligible.&#xD;
&#xD;
          4. Diagnostic laparoscopy is not mandated and can be performed as clinically indicated.&#xD;
&#xD;
          5. Eligible for surgery with curative intent&#xD;
&#xD;
          6. A female participant is eligible to participate if she is not pregnant (see Appendix&#xD;
             3), not breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
               1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR&#xD;
&#xD;
               2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the&#xD;
                  treatment period and for at least 120 days after the last dose of study&#xD;
                  treatment.&#xD;
&#xD;
          7. The participant (or legally acceptable representative if applicable) provides written&#xD;
             informed consent for the trial.&#xD;
&#xD;
          8. Measurable or non-measurable disease by RECIST 1.1 will be allowed.&#xD;
&#xD;
          9. Is willing to provide tissue for correlative studies from the primary tumor lesion at&#xD;
             baseline and at time of surgery. Is willing to provide blood and stool samples for all&#xD;
             ordered studies.&#xD;
&#xD;
         10. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
             Evaluation of ECOG is to be performed within 7 days prior to the date of allocation.&#xD;
&#xD;
         11. Have adequate organ function as defined in the following table (Table 1). Table 1&#xD;
             Adequate Organ Function Laboratory Values System Laboratory Value Hematological&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1500/µL&#xD;
&#xD;
               -  Platelets ≥100 000/µL&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La Renal&#xD;
&#xD;
               -  Creatinine OR Measured or calculatedb creatinine clearance (GFR can also be used&#xD;
                  in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL/min for participant with&#xD;
                  creatinine levels &gt;1.5 × institutional ULN Hepatic&#xD;
&#xD;
               -  Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total&#xD;
                  bilirubin levels &gt;1.5 × ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤2.5 × ULN Coagulation&#xD;
&#xD;
               -  International normalized ratio (INR) OR prothrombin time (PT) Activated partial&#xD;
                  thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving&#xD;
                  anticoagulant therapy as long as PT or aPTT is within therapeutic range of&#xD;
                  intended use of anticoagulants&#xD;
&#xD;
        ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST&#xD;
        (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular&#xD;
        filtration rate; ULN=upper limit of normal.&#xD;
&#xD;
          1. Criteria must be met without erythropoietin dependency and without packed red blood&#xD;
             cell (pRBC) transfusion within last 2 weeks.&#xD;
&#xD;
          2. Creatinine clearance (CrCl) should be calculated per institutional standard. Note:&#xD;
             This table includes eligibility-defining laboratory value requirements for treatment;&#xD;
             laboratory value requirements should be adapted according to local regulations and&#xD;
             guidelines for the administration of specific chemotherapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
               1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to&#xD;
                  allocation (see Appendix 3). If the urine test is positive or cannot be confirmed&#xD;
                  as negative, a serum pregnancy test will be required.&#xD;
&#xD;
               2. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or&#xD;
                  with an agent directed to another stimulatory or co-inhibitory T-cell receptor&#xD;
                  (eg, CTLA-4, OX 40, CD137).&#xD;
&#xD;
               3. Previous or concurrent malignancy, except for adequately treated basal cell or&#xD;
                  squamous cell skin cancer, in situ cervical cancer, or any other cancer for which&#xD;
                  the patient has been previously treated and the lifetime recurrence risk is less&#xD;
                  than 30%.&#xD;
&#xD;
               4. Has received prior systemic anti-cancer therapy including investigational agents&#xD;
                  within 4 weeks prior to allocation.&#xD;
&#xD;
                  Note: Participants must have recovered from all AEs due to previous therapies to&#xD;
                  ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible.&#xD;
&#xD;
                  Note: If participant received major surgery, they must have recovered adequately&#xD;
                  from the toxicity and/or complications from the intervention prior to starting&#xD;
                  study treatment.&#xD;
&#xD;
               5. Has received prior radiotherapy within 2 weeks of start of study treatment.&#xD;
                  Participants must have recovered from all radiation-related toxicities, not&#xD;
                  require corticosteroids, and not have had radiation pneumonitis.&#xD;
&#xD;
               6. Has received a live vaccine within 30 days prior to the first dose of study drug.&#xD;
                  Examples of live vaccines include, but are not limited to, the following:&#xD;
                  measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,&#xD;
                  Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines&#xD;
                  for injection are generally killed virus vaccines and are allowed; however,&#xD;
                  intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are&#xD;
                  not allowed.&#xD;
&#xD;
               7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid&#xD;
                  therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other&#xD;
                  form of immunosuppressive therapy within 7 days prior to the first dose of study&#xD;
                  drug.&#xD;
&#xD;
               8. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its&#xD;
                  excipients.&#xD;
&#xD;
               9. Has active autoimmune disease that has required systemic treatment in the past 2&#xD;
                  years (i.e. with use of disease modifying agents, corticosteroids or&#xD;
                  immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or&#xD;
                  physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
                  insufficiency, etc.) is not considered a form of systemic treatment.&#xD;
&#xD;
              10. Has a history of (non-infectious) pneumonitis that required steroids or has&#xD;
                  current pneumonitis.&#xD;
&#xD;
              11. Has an active infection requiring systemic therapy.&#xD;
&#xD;
              12. Has a known history of Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
              13. Has a known history of active TB (Bacillus Tuberculosis).&#xD;
&#xD;
              14. Has a history or current evidence of any condition, therapy, or laboratory&#xD;
                  abnormality that might confound the results of the study, interfere with the&#xD;
                  subject's participation for the full duration of the study, or is not in the best&#xD;
                  interest of the subject to participate, in the opinion of the treating&#xD;
                  investigator.&#xD;
&#xD;
              15. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
                  cooperation with the requirements of the trial.&#xD;
&#xD;
              16. Is pregnant or breastfeeding, or expecting to conceive or father children within&#xD;
                  the projected duration of the study, starting with the screening visit through&#xD;
                  120 days after the last dose of trial treatment.&#xD;
&#xD;
              17. Is currently participating in or has participated in a study of an&#xD;
                  investigational agent or has used an investigational device within 4 weeks prior&#xD;
                  to the first dose of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Catenacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Catenacci</last_name>
    <phone>773-702-7596</phone>
    <email>dcatenac@bsd.uchicago.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Of Chicago Medicine Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Catenacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

